Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Immunovant (IMVT) Operating Leases (2020 - 2024)

Immunovant filings provide 5 years of Operating Leases readings, the most recent being $138000.0 for Q1 2024.

  • Quarterly Operating Leases rose 193.62% to $138000.0 in Q1 2024 from the year-ago period, while the trailing twelve-month figure was $138000.0 through Mar 2024, up 193.62% year-over-year, with the annual reading at $138000.0 for FY2024, 193.62% up from the prior year.
  • Operating Leases hit $138000.0 in Q1 2024 for Immunovant, up from $47000.0 in the prior quarter.
  • Across five years, Operating Leases topped out at $4.2 million in Q2 2020 and bottomed at $47000.0 in Q1 2023.
  • Average Operating Leases over 5 years is $1.6 million, with a median of $1.2 million recorded in 2022.
  • The largest annual shift saw Operating Leases crashed 96.14% in 2023 before it surged 193.62% in 2024.
  • Immunovant's Operating Leases stood at $2.4 million in 2020, then decreased by 17.56% to $2.0 million in 2021, then plummeted by 84.48% to $306000.0 in 2022, then tumbled by 84.64% to $47000.0 in 2023, then surged by 193.62% to $138000.0 in 2024.
  • Per Business Quant, the three most recent readings for IMVT's Operating Leases are $138000.0 (Q1 2024), $47000.0 (Q1 2023), and $306000.0 (Q4 2022).